

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	37
PREAMBLE.....	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION.....	14
1. Exposure data.....	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS	33
BITUMENS AND BITUMEN EMISSIONS.....	39
1. Exposure Data	39
1.1 Identification of the agent: definitions and classifications.....	39
1.2 Methods of analysis	51
1.3 Production and use.....	55
1.4 Occurrence and exposure	69
1.5 Regulations and guidelines	88
2. Cancer in Humans.....	90
2.1 Introduction	90
2.2 Cohort studies	91
2.3 Case-control studies.....	124
2.4 Meta-analyses.....	138
3. Cancer in Experimental Animals	140
3.1 Mouse.....	140

3.2	Rat	153
3.3	Rabbit	154
3.4	Guinea-pig.....	155
4.	Mechanistic and Other Relevant Data.....	155
4.1	Overview of the mechanisms of carcinogenesis of PAHs	155
4.2	Absorption, distribution, metabolism, and excretion of bitumens and bitumen fume	164
4.3	Genetic and related effects.....	170
4.4	Other effects relevant to carcinogenesis	189
4.5	Mechanistic considerations	193
5.	Summary of Data Reported.....	196
5.1	Exposure data	196
5.2	Human carcinogenicity data	197
5.3	Animal carcinogenicity data	200
5.4	Mechanistic and other relevant data.....	202
6.	Evaluation	203
6.1	Cancer in humans	203
6.2	Cancer in experimental animals.....	203
6.3	Mechanistic and other relevant data.....	203
6.4	Overall evaluation	204
6.5	Rationale	204
	References.....	204

SOME N- AND S-HETEROCYCLIC POLYCYCLIC AROMATIC HYDROCARBONS

1.	Exposure Data	221
1.1	Identification of the agents.....	221
1.2	Analysis	225
1.3	Production and use.....	226
1.4	Occurrence and exposure	226
1.5	Regulations and guidelines	229
2.	Cancer in Humans.....	229
3.	Cancer in Experimental Animals	229
3.1	Benz[<i>a</i>]acridine	229
3.2	Benz[<i>c</i>]acridine.....	230
3.3	Dibenz[<i>a,h</i>]acridine.....	235
3.4	Dibenz[<i>a,j</i>]acridine	241
3.5	Dibenz[<i>c,h</i>]acridine.....	246
3.6	Carbazole	248
3.7	7 <i>H</i> -Dibenzo[<i>c,g</i>]carbazole	252
3.8	Dibenzothiophene	257
3.9	Benzo[<i>b</i>]naphtho[2,1- <i>d</i>]-thiophene.....	257
4.	Mechanistic and Other Relevant Data.....	258
4.1	Benz[<i>a</i>]acridine	258
4.2	Benz[<i>c</i>]acridine.....	260
4.3	Dibenz[<i>a,h</i>]acridine.....	262
4.4	Dibenz[<i>a,j</i>]acridine	266
4.5	Dibenz[<i>c,h</i>]acridine.....	271

4.6	Carbazole	274
4.7	7 <i>H</i> -Dibenzo[<i>c,g</i>]carbazole	275
4.8	Dibenzothiophene	280
4.9	Benzo[<i>b</i>]naphtho[2,1- <i>d</i>]thiophene.....	283
5.	Summary of Data Reported.....	285
5.1	Exposure data	285
5.2	Human carcinogenicity data	285
5.3	Animal carcinogenicity data	285
5.4	Mechanistic and other relevant data.....	287
6.	Evaluation	292
6.1	Cancer in humans	292
6.2	Cancer in experimental animals	292
6.3	Overall evaluation	292
	References.....	292
	GLOSSARY	305
	LIST OF ABBREVIATIONS	309
	CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS.....	311

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

